Hepatitis B: Difference between revisions
ClaireLewis (talk | contribs) No edit summary |
|||
(5 intermediate revisions by 3 users not shown) | |||
Line 10: | Line 10: | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
{{Acute hepatitis causes}} | |||
==Evaluation== | ==Evaluation== | ||
*AST, ALT > 1000s | *[[LFTs]] | ||
*Elevated bilirubin | **AST, ALT > 1000s | ||
*Elevated alk phophatase | **Elevated bilirubin | ||
**Elevated alk phophatase | |||
*Elevated INR | *Elevated INR | ||
*Acute hepatitis panel | *CBC, BMP | ||
{| | *Assess for alternative etiologies of symptoms as appropriate (see: [[jaundice]], [[RUQ pain]], [[nausea/vomiting]] | ||
{{Acute hepatitis panel}} | |||
{| {{table}} | |||
| align="center" style="background:#f0f0f0;"|'''Clinical Scenario''' | |||
| align="center" style="background:#f0f0f0;"|'''HBsAg''' | |||
| align="center" style="background:#f0f0f0;"|'''anti-HBc''' | |||
| align="center" style="background:#f0f0f0;"|'''anti-HBs''' | |||
|- | |- | ||
| | | Susceptible to infection||negative||negative||negative | ||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| | | Immune due to natural infection||negative||positive||positive | ||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| | | Immune due to Hep B infection||negative||negative||positive | ||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| | | Acutely infected||positive||anti-HBc- positive; IgM anti-HBc- positive||negative | ||
| | |||
| | |||
| | |||
| | |||
|- | |- | ||
| | | Chronically infected||positive||anti-HBc- positive; IgM anti-HBc- negative||negative | ||
| | |||
| | |||
| | |||
| | |||
|} | |} | ||
Line 58: | Line 43: | ||
*Supportive care for acute disease | *Supportive care for acute disease | ||
{{Hepatitis B post exposure prophylaxis}} | {{Hepatitis B post exposure prophylaxis}} | ||
==Disposition== | ==Disposition== | ||
*Consider admission for: | *Consider admission for: | ||
Line 68: | Line 53: | ||
==See Also== | ==See Also== | ||
*[[ | *[[Viral hepatitis]] | ||
*[[Acute hepatitis]] | *[[Acute hepatitis]] | ||
*[[Jaundice]] | *[[Jaundice]] | ||
==External Links== | ==External Links== | ||
*[[Antibiotics (By_Diagnosis)]] | *[[Antibiotics (By_Diagnosis)]] |
Revision as of 18:07, 4 June 2020
Background
- Blood-borne virus
- Incubation period: 1-3 months
- Virus can cause acute, chronic, or asymptomatic infection
Clinical Features
Differential Diagnosis
Causes of acute hepatitis
- Acetaminophen toxicity (most common cause of acute liver failure in the US[1])
- Viral hepatitis
- Toxoplasmosis
- Acute alcoholic hepatitis
- Toxins
- Ischemic hepatitis
- Autoimmune hepatitis
- Wilson's disease
Evaluation
- LFTs
- AST, ALT > 1000s
- Elevated bilirubin
- Elevated alk phophatase
- Elevated INR
- CBC, BMP
- Assess for alternative etiologies of symptoms as appropriate (see: jaundice, RUQ pain, nausea/vomiting
Interpreting Acute Hepatitis Panel Results
Anti-hepatitis A, IgM | Hepatitis B surface antigen | Anti-hepatitis B core, IgM | Anti-hepatitis C | Interpretation |
---|---|---|---|---|
Positive | Negative | Negative | Negative | Acute hepatitis A |
Negative | Positive | Positive | Negative | Acute hepatitis B |
Negative | Positive | Negative | Negative | Chronic hepatitis B infection |
Negative | Negative | Positive | Negative | Acute hepatitis B; quantity of hepatitis B surface antigen is too low to detect |
Negative | Negative | Negative | Positive | Acute or chronic hepatitis C; additional tests are required to make the determination |
Clinical Scenario | HBsAg | anti-HBc | anti-HBs |
Susceptible to infection | negative | negative | negative |
Immune due to natural infection | negative | positive | positive |
Immune due to Hep B infection | negative | negative | positive |
Acutely infected | positive | anti-HBc- positive; IgM anti-HBc- positive | negative |
Chronically infected | positive | anti-HBc- positive; IgM anti-HBc- negative | negative |
Management
- Supportive care for acute disease
Hepatitis B Post-Exposure Prophylaxis
Treatment is generally initiated after coordination with occupational health and infectious disease service and based the the exposed patient's vaccination history[2]
Unvaccinated
- If the source is HBsAg(+) then give HBIG x1 and initiate HBV vaccine in two separate sites
- If source is HGsAG(-) then start the HBV vaccine series
- If source blood is unavailable and high risk then give HBIG x1 initiate the HBV series
- If source blood is low risk and unavailable then begin HBV series
Previously vaccinated non responder (one series)
Non responder status is defined as anti-has <10mIU/mL
- If the source is HBsAg(+) then give HBIG x 1 and begin revaccination series
- Can also opt to perform second HBIG administration in one month
- If source is HBsAg(-) then no treatment is needed
- If source blood is unavailable and high risk then treat as if HBsAg(+)
Previously vaccinated non responder (two series)
Non responder status is defined as anti-has <10mIU/mL
- If the source is HBsAg(+) then give HBIG x2 and no HBV series
- If source is HGsAG(-) then no treatment is needed
- If source blood is unavailable then initiate the HBV series
Treatment Dosing
No contraindications for pregnancy or breast feeding
- HBIG 0.06 mL/kg IM
- Give in opposite arm from hepatitis B vaccine if patient also receiving vaccine
- Vaccination series: HBV vaccine options:
- Engerix-B 20mcg IM
- Recombivax HB 10mcg IM
Disposition
- Consider admission for:
- INR >2, Bilirubin >30, hypoglycemia
- Any GI bleeding
- Intractable pain, inability to tolerate PO
- Significant comorbidity/immunocompromised or age >50 years
See Also
External Links
References
- ↑ Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002 Dec 17; 137(12): 947-54.
- ↑ Postexposure prophylaxis to prevent hepatitis b virus infection. CDC MMWR http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5516a3.htm?s_cid=rr5516a3_e